Effects of injection Shenkang and alprostadil combination on contrast-induced nephropathy in patient with diabetes complicated with mild to moderate renal insufficiency
DOI:
https://doi.org/10.3329/bjp.v12i3.32070Keywords:
Alprostadil, Contrast-induced nephropathy, Diabetes, Renal insufficiency, ShenkangAbstract
The diabetic patients (n=109) with mild or moderate renal insufficiency underwent coronary intervention were randomly divided into control group and observation group. The patients in observation group were treated with injection Shenkang and alprostadil before operation. The results showed that the level of serum creatinine, creatinine clearance and blood urea nitrogen had no significant difference (p>0.05) before and postoperative day 1 and day 2 in both groups. However, the value of serum creatinine, creatinine clearance and blood urea nitrogen were significantly different on post-operative day 3 (p<0.05). The incidence of contrast-induced nephropathy was 14.8% in control group, and markedly higher than observation group (3.6%) (p<0.05). Shenkang injection combined with alprostadil injection decreased the incidence of contrast-induced nephropathy in elderly patients with diabetes mellitus complicated with mild to moderate renal insufficiency.
Downloads
17
12
References
Cirit M, Toprak O, Yesil M, Bayata S, Postaci N, Pupim L, Esi E. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract. 2006; 104: c20-27.
Feldkamp T, Kribben A. Contrast media induced nephropathy: Definition, incidence, outcome, pathophysiology, risk factors and prevention. Minerva Med. 2008; 99: 177-96.
Fen XZ. Wang systematic mechanism of Rhubarb and Chloostatum on restoring signaling pathway of renal tubular epithelium in rats with contrast-induced nephropathy. Shanghai J Tradit Chin Med. 2013; 47: 37-38.
Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. Am J Roentgenol. 2004; 183: 167389.
Isobe S, Yamada T, Sato K, Murohara T. Diabetes with preserved renal function is an independent risk factor for renal function deterioration after coronary computed tomography angiography. J Comput Assist Tomogr. 2013; 37: 750-54.
Jiang ZW, Lv YY, Xia JL. Clinical observation on the treatment of chronic renal failure with Shenkang injection. J Chin Med Univ. 2011; 40: 941-45.
Kato K, Sato N, Yamamoto T, Iwasaki YK, Tanaka K, Mizuno K. Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization. Circulation 2008; 72: 1499-505.
Khanal S, Attallah N, Smith DE, Kline-Rogers EM, Share DA, O'Donnell MJ, Moscucci M. Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions. Am J Med. 2005; 118: 843-49.
Li WM, Xue JY. Comparison of the progress of contrast-induced nephropathy. Chin J Circ. 2010; 25: 325-26.
Li W, Zhan F, Wu W. Effect of alprostadil on patients with acute kidney injury. Chin Trop Med. 2012; 11: 42.
Liao SJ, Yang C, Jiang HQ. Effect and safety of alprostadil in the treatment of elderly patients with diabetes mellitus and chronic kidney disease. J Zhongshan Univ. 2015; 36: 120-25.
Lu ZY, Cheng DS, Yin JY, Wu R, Zhang GY, Zhao Q, Wang NS, Wang F, Liang MY. Antithrombin III protects against contrast-induced nephropathy. EBioMedicine 2017; 17: 101-07.
Lv RH, Zhang FR, Gao YB. Chinese medicine stage syndrome evaluation criteria of diabetes. Chinese medicine diagnosis treatment of diabetes. 1999, pp 363-65.
Menting TP, Sterenborg TB, DeWaal Y, Donders R, Wever KE, Lemson MS, van der Vliet JA, Wetzels JF, Schultzekool LJ, Warle MC. Remote ischemic preconditioning to reduce contrast-induced nephropathy: A randomized controlled trial. Eur J Vasc Endovasc Surg. 2015; 50: 52732.
Miao Y, Zhong Y, Yan H, Li W, Wang BY, Jin J. Alprostadil plays a protective role in contrast-induced nephropathy in the elderly. Int Urol Nephrol. 2013; 45: 1179-85.
Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, Farid N, McManamon PJ. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. N Engl J Med. 1989; 320: 14353.
Rundback JH, Nahl D, Yoo V. Contrast-induced nephropathy. J Vasc Surg. 2011; 54: 575-79.
Soma VR, Cavusoglu E, Vidhun R, Frishman WH, Sharma SK. Contrast associated nephropathy. Heart Dis. 2002; 4: 372-79.
Wang XD, Shen JP. Experimental study on the effect of Shenkang injection on prevention of contrast-induced nephropathy after aged coronary artery disease. Nanjing Univ Tradit Chin Med. 2013; 29: 16-17.
Xu RH, Ma GZ, Cai ZX, Chen P, Zhu ZD, Wang WL. Combined use of hydration and alprostadil for preventing contrast-induced nephropathy following percutaneous coronary intervention in elderly patients?Exp Ther Med. 2013; 6: 863-67?
Zhao B, Zhao Q, Li J, Xing T, Wang F, Wang N. Renalase protects against contrast-induced nephropathy in Sprague-Dawley rats. PLoS One. 2015; 10: e0116583.
Zhao K, Li Y, Zhang H. Role of Dongchongxiacao (Cordyceps) in prevention of contrast-induced nephropathy in patients with stable angina pectoris. J Tradit Chin Med. 2013; 33: 283-86.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
